NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.
Novartis · Metastatic Neuroendocrine Prostate Cancer
Phase 1
Active, not recruiting
31
2026-07
Industry sponsor intelligence
NovartisClinical Pipeline.
Lead-sponsor view of Novartis's indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 39
- Recruiting
- 3
- Active
- 4
- Completed
- 28
- Results posted
- 20
- Avg enrollment
- 301
Pipeline overview
Programs by phase and activity.
Velocity
Novartis trials by start year
Study start year · indexed snapshot
Development
Trials by phase
38phase labels
Early Phase 10
Phase 111
Phase 213
Phase 310
Phase 44
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Pasireotide → | 28 | 8 | 12 | 7 | 1 | 1 |
| Goserelin → | 5 | 1 | 1 | 2 | 1 | 4 |
| Calcitonin → | 2 | 0 | 0 | 1 | 1 | 0 |
| Nesiritide → | 2 | 0 | 0 | 0 | 1 | 0 |
| Leuprolide → | 1 | 0 | 0 | 1 | 0 | 1 |
| Octreotide → | 1 | 0 | 0 | 1 | 0 | 1 |
| Degarelix → | 2 | 2 | 0 | 0 | 0 | 2 |
Active peptide trials
In motion now.
NCT IDStudyPhase / statusEnrollmentUpdated
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Novartis · Early Breast Cancer
Phase 3
Recruiting
1,400
2026-07
[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer
Novartis · Breast Cancer
Phase 1
Active, not recruiting
28
2026-07
Roll-over Study to Allow Continued Access to Ribociclib
Novartis · Metastatic Breast Cancer
Phase 4
Active, not recruiting
134
2026-06
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
Novartis · Somatostatin Receptor Positive (SSTR+) · Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Phase 3
Recruiting
240
2026-04
A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer
Novartis · Early Breast Cancer
Phase 3
Active, not recruiting
5,101
2026-04
A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study
Novartis · Metastatic Castration-Resistant Prostate Cancer
Phase 1
Recruiting
106
2025-12
Completed trials
Finished registry records.
NCT IDStudyPhase / statusEnrollmentUpdated
Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.
Novartis · Breast Cancer
Phase 2
Completed
327
2026-07
Secondary Use of PARALLEL-HF Data
Novartis · Chronic Heart Failure and Reduced Ejection Fraction (HFrEF)
Not applicable
Completed
236
2026-04
The VALIDATE Study of Valsartan for Patients With Early Stage Heart Failure
Novartis · Hypertension · Congestive Heart Failure
Phase 4
Completed
37
2023-10
Study of Efficacy and Safety of AMG 334 in Adult Episodic Migraine Patients
Novartis · Episodic Migraine
Phase 3
Completed
900
2021-10
Head-to-head Study of Erenumab Against Topiramate in Patients With Episodic and Chronic Migraine
Novartis · Migraine
Phase 4
Completed
777
2021-10
An Extension Study to Assess the Long-Term Safety and Efficacy of Pasireotide in Participants With Acromegaly
Novartis · Acromegaly
Phase 2
Completed
30
2021-09
Extension Study to Assess the Safety and Efficacy of Pasireotide in Participants With Cushing's Disease
Novartis · Cushing Disease
Phase 2
Completed
19
2021-06
3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA Trial
Novartis · Neuroendocrine Carcinoma of the Lung and Thymus
Phase 2
Completed
124
2021-04
Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease
Novartis · Carcinoid Tumor · Acromegaly
Phase 1
Completed
85
2020-12
Pharmacokinetics and Safety of Single Subcutaneous Pasireotide (SOM230) in Subjects With Varying Degrees of Hepatic Function
Novartis · Hepatic Cirrhosis · Alcoholism
Phase 1
Completed
34
2020-12
Showing 10 of 28 studies
Search sponsor records
All Novartis studies.
This page groups studies where Novartis is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
39 matching studies
Last registry update first
Recent updates
Latest registry movement.
NCT06379217NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.Jul 24, 2026NCT05827081Phase IIIb Study of Ribociclib + ET in Early Breast CancerJul 17, 2026NCT03671330Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.Jul 8, 2026NCT05870579[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast CancerJul 6, 2026NCT05161195Roll-over Study to Allow Continued Access to RibociclibJun 23, 2026NCT06784752Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NETApr 30, 2026NCT07527767Secondary Use of PARALLEL-HF DataApr 14, 2026NCT03701334A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast CancerApr 1, 2026NCT06531499A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) StudyDec 31, 2025NCT00241098The VALIDATE Study of Valsartan for Patients With Early Stage Heart FailureOct 18, 2023